Ed­i­to­r­i­al: Did Rick Paz­dur's big 'no' on Lil­ly's Chi­na-born PD-1 al­so spell the end for price dis­rup­tion?

Eli Lil­ly has a big de­ci­sion com­ing Thurs­day as an FDA ad­vi­so­ry com­mit­tee con­sid­ers the mer­its of PD-1 block­er sin­til­imab, a drug de­vel­oped in Chi­na with part­ner In­novent. That ad­comm could swing ei­ther way — but if FDA on­col­o­gy head Rick Paz­dur’s word reigns supreme, sin­til­imab is al­ready dead in the wa­ter.

Paz­dur and FDA in­sid­ers think they have a com­pelling case against sin­til­imab for one rea­son: The drug’s piv­otal tri­al was con­duct­ed in Chi­na alone with re­sults that might not trans­late in­to a more het­eroge­nous US pa­tient pool.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER